Journal article
Evaluation of PSA decline patterns in the Chinese subgroup of LIBERTAS, a phase 3 study of apalutamide plus continuous versus intermittent androgen deprivation therapy in metastatic castration-sensitive prostate cancer.
Qiang Dong, Lei Li, Zhenhua Li, Jiaju Lyu, Chunxi Wang, Wanlong Tan, Shaogang Wang, Junhui Jiang, Alex Dos Santos, Sukie Shopeju, Amitabha Bhaumik, Suneel Dinkar Mundle, Sharon McCarthy, Anildeep Singh, Lijun Zhang, Na Chen, Mark A Wildgust, Arun Azad, Neeraj Agarwal
Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2026
Abstract
154 Background: LIBERTAS is a global phase 3 study evaluating apalutamide (APA) plus intermittent versus continuous androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The study aims to determine reduces hot flash burden compared with APA + continuous ADT and whether APA + intermittent ADT provides noninferior radiographic progression-free survival (rPFS). Initial findings demonstrated that treatment with 6 months of APA + ADT resulted in rapid and deep PSA responses in most patients with mCSPC. This abstract presents PSA response results from patients enroll..
View full abstract